Medical technology company SciBase Holding AB (STO:SCIB) announced on Wednesday a strategic collaboration with Italian firm Kilabs srl to enhance skin cancer diagnostics in Italy.
Kilabs, recognized for its expertise in dermatology, will introduce SciBase's Nevisense technology, tailored for the Italian market, with an expected launch in the first half of 2025. To facilitate a smooth rollout, Kilabs will begin market preparations immediately.
Italy faces a rising incidence of skin cancer, with mortality rates increasing, especially among men. Nevisense offers a non-invasive, advanced approach to early melanoma detection, aiming to improve patient outcomes significantly.
CEO Michelangelo Simonelli, supported by experts Alessandro Cappella and Giuseppe Romano, is leading Kilabs' integration of Nevisense into clinical practice. This collaboration reflects Kilabs' dedication to healthcare innovation and enhanced standards in Italian dermatology.
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
TransCode Therapeutics enrols three patients in Cohort 3 of TTX-MC138 Phase 1 clinical trial
Biohit partners with Restalyst to enhance early gastric cancer detection
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Oxford BioDynamics reports high accuracy for blood-based colorectal cancer test
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer